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Because metabolites are hypothesized to play key
roles as markers and effectors of cardiometabolic
diseases, recent studies have sought to annotate
the genetic determinants of circulating metabolite
levels. We report a genome-wide association study
(GWAS) of 217 plasma metabolites, including >100
not measured in prior GWAS, in 2076 participants of
the Framingham Heart Study (FHS). For the majority
of analytes, we find that estimated heritability
explains >20% of interindividual variation, and that
variation attributable to heritable factors is greater
than that attributable to clinical factors. Further, we
identify 31 genetic loci associated with plasma me-
tabolites, including 23 that have not previously been
reported. Importantly, we include GWAS results for
all surveyed metabolites and demonstrate how this
information highlights a role for AGXT2 in cholesterol
ester and triacylglycerol metabolism. Thus, our study
outlines the relative contributions of inherited and
clinical factors on the plasma metabolome and pro-
vides a resource for metabolism research.130 Cell Metabolism 18, 130–143, July 2, 2013 ª2013 Elsevier Inc.INTRODUCTION
Recent studies have begun to integrate genomic and metabolo-
mic data in human cohorts (Demirkan et al., 2012; Gieger et al.,
2008; Hicks et al., 2009; Illig et al., 2010; Kettunen et al., 2012;
Suhre et al., 2011a, 2011b; Tukiainen et al., 2012). Because
metabolites are hypothesized to play key roles as markers and
effectors of cardiometabolic diseases, these efforts seek to
both refine and expand our understanding of the causal determi-
nants of circulating metabolite levels. Studies to date have been
notable for the identification of loci at enzymes or transport pro-
teins directly involved with a given metabolite’s disposition
(Suhre and Gieger, 2012). In turn, many of these loci have shown
relatively large effect sizes on metabolite levels, as compared to
findings in genome wide association studies (GWAS) for com-
mon diseases.
Whereas genetically informative deoxyribonucleic acid se-
quence is limited to four distinct chemical motifs, endogenous
metabolites span a variety of compound classes with significant
differences in size and polarity, across a wide range of concen-
trations. As a consequence, no single analytical method is
able to accommodate the chemical diversity of the entire
metabolome. Thus, GWAS of metabolite traits to date have
employed various methodologies including nuclear magnetic
resonance spectroscopy and mass spectrometry (MS), with
Table 1. Sample Clinical Characteristics
Characteristic N = 2076
Age, years 55 (10)
Women, n (%) 1062 (51)
Systolic blood pressure, mmHg 127 (19)
Diastolic blood pressure, mmHg 75 (10)
Body-mass index, kg/m2 27.6 (5.0)
Antihypertensive treatment, n (%) 424 (20)
Diabetes mellitus, n (%) 137 (7)
Current smoker, n (%) 396 (19)
Prevalent cardiovascular disease, n (%) 49 (2)
Total cholesterol, mg/dl 207 (37)
HDL cholesterol, mg/dl 49 (15)
Characteristics of the 2076 individuals in the Framingham Offspring
Cohort who underwent metabolite profiling and GWAS are shown. Data
represent means (standard deviation) unless otherwise noted.
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(Rhee and Gerszten, 2012). Even with a given analytical tool,
distinct methods have been required to survey polar versus
lipid analytes. We have developed a LC-MS based metabolo-
mics platform that measures a total of 217 analytes (113 polar
analytes and 104 lipid analytes), including >100 not measured
in prior GWAS.
In the current study, we performed metabolite profiling on
plasma obtained from 2076 individuals in the Framingham Heart
Study (FHS). The family-based structure of this cohort, as well
as its rich cardiometabolic phenotyping, presents a unique
opportunity to study the relative contributions of heritable,
environmental, and clinical factors influencing the plasma
metabolome. For many metabolites, we confirm that a substan-
tial fraction of metabolite variability is heritable (Shah et al., 2009;
Kettunen et al., 2012), often exceeding the influence ofmeasured
clinical factors. Using GWAS, we also identify numerous locus-
metabolite associations and demonstrate how these findings
complement and extend prior association studies of complex
human traits. Finally, we include a proof-of-principle demonstra-
tion of how the breadth of metabolite, genotype, and phenotype
data we present in FHS can motivate functional studies to pro-
vide biological insight.
RESULTS
A total of 2076 participants of the FHS Offspring Cohort,
including 873 sibships, underwent metabolic profiling and
genome-wide genotyping. The mean age was 55 years and
51% of participants were women (Table 1).
Relative Contributions of Heritable and Clinical Factors
to Metabolite Levels
The estimated proportion of interindividual metabolite variation
attributable to heritable factors (including genome-wide signifi-
cant loci) compared with clinical factors (age, sex, systolic blood
pressure, antihypertensive medication use, body-mass index,
diabetes, smoking status, and prevalent cardiovascular disease)
is displayed in Figure 1A and Figure S1. Metabolites most influ-enced by clinical variables include the nicotine metabolite cotin-
ine (70% of variation explained by clinical factors, 66% by
smoking alone), and fructose/glucose/galactose (45%). Adjust-
ment for renal function in secondary analyses did not appre-
ciably change results (Table S1).
For the majority of metabolites, the proportion of variation
attributable to heritable factors was greater than that of clinical
factors: for 93% of metabolites assayed, measured clinical fac-
tors accounted for 20% or less of interindividual variation. By
contrast, estimated heritability explained greater than 20% of
the interindividual variation for 66% of metabolites. Amino acids
and other polar analytes had the highest heritability estimates,
including carnosine (h2 = 0.86, p = 6.8 3 104), anthranilic acid
(h2 = 0.84, p = 3.2 3 1014), and glutamate (h2 = 0.82, p =
9.1 3 1013), whereas heritability estimates for lipid analytes
were lower, with the highest estimate for lysophosphatidylcho-
line (LPC) 22:6 (h2 = 0.46, p = 2.0 3 107).
Heritability estimates for essential amino acids were lower
than for nonessential amino acids: mean h2 = 0.29, range
0.14–0.43, versusmean h2 = 0.53, range 0.15–0.82, respectively;
p = 0.01 (Figure 1B). Similarly, none of the essential amino acids
were associated with genetic loci at a genome-wide significant
level, whereas five of the ten nonessential amino acidsmonitored
by our platform had genome-wide significant findings in our
study. Conversely, clinical factors explained a greater proportion
of variation for essential versus nonessential amino acids (mean
R2 for clinical model = 0.17, range 0.04–0.34, versus mean R2 =
0.09, range 0.03–0.16, respectively). These findings align with
the relative contributions of endogenous (inherited) versus die-
tary (environmental) factors for these small molecules and pro-
vide internal validation for the observed distribution ofmetabolite
heritability.
GWAS Identifies 31 Genetic Loci Associated with
Plasma Metabolite Levels
Genome-wide associations are displayed in Table 2, and quan-
tile-quantile and linkage disequilibrium-plots for these associa-
tions are displayed in Figures S2 and S3. Of 217 metabolites
analyzed, 64 had at least one genome-wide significant locus.
Conversely, 31 discrete loci were associated with at least one
metabolite trait and a number of loci were associated with mul-
tiple metabolites (Table 2). Our data both replicate previously
identified associations as well as identify numerous novel
locus-metabolite associations (Figure 2). These novel findings
include loci that span genes encoding proteins with a direct
biochemical relationship with a given metabolite, loci previously
associated with complex human disease traits, and loci with no
prior significant associations in GWAS.
Confirmation of Previously Established Locus-
Metabolite Associations
Eight of the locus-metabolite associations identified in our
study have been previously reported, and seven of these eight
associations involve genes directly related to the transport or
synthesis of a given metabolite (Figure 2). For example, we
replicate prior associations between loci at SLC16A9, which en-
codes a carnitine efflux transporter, and carnitine; PRODH (pro-
line dehydrogenase), which encodes the enzyme that catalyzes
the first step of proline catabolism, and proline; and PHGDHCell Metabolism 18, 130–143, July 2, 2013 ª2013 Elsevier Inc. 131
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Figure 1. Genetic Architecture of the Human Plasma Metabolome
(A) The percent interindividual variation for positively charged, polar metabolites explained by clinical (black) and genetic factors: top SNP (green), second top
SNP (red), other genetic factors (gray). Clinical factors include age, sex, systolic blood pressure, antihypertensive medication use, diabetes mellitus, smoking
status, body-mass index, and prevalent cardiovascular disease.
(B) Data summarized for nonessential and essential amino acids. See also Figure S1 and Table S1.
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Metabolomics GWAS in the FHS(phosphoglycerate dehydrogenase), which encodes the enzyme
that catalyzes the first and rate-limiting step of serine biosyn-
thesis, and serine (Suhre et al., 2011a). A locus at SLC16A10,
which encodes a tyrosine and phenylalanine transporter, has
previously been associated with the ratio of isoleucine/tyrosine
(Suhre et al., 2011a) and the ratio of alanine/tyrosine (Kettunen
et al., 2012); we show that this association holds true for tyrosine132 Cell Metabolism 18, 130–143, July 2, 2013 ª2013 Elsevier Inc.alone. We also identify an association between a locus at AGXT2
(alanine-glyoxylate aminotransferase-2) and its enzyme sub-
strate b-aminoisobutyric acid. Prior work has shown an associa-
tion between this locus and urinary levels of b-aminoisobutyric
acid (Suhre et al., 2011b).
Further, we confirm the association between glycine and
a variant at CPS1 (carbamoyl phosphate synthase 1), which
Cell Metabolism
Metabolomics GWAS in the FHSencodes the enzyme that catalyzes the first committed step
of the urea cycle. Although not a urea cycle intermediate,
glycine can react with arginine (a urea cycle intermediate) to
yield ornithine (a urea cycle intermediate) and guanidinoacetic
acid. Methylation of guanidinoacetic acid yields creatine, which
is ultimately metabolized to creatinine. Notably, we identify a
novel association between the CPS1 locus and creatine,
whereas others have identified an association between CPS1
common variants and creatinine (Ko¨ttgen et al., 2010). Thus,
complementary metabolomic data sets are able to extend
the network of locus-metabolite associations along defined
biochemical pathways.
Finally, we replicate the association between the FADS1-3
(fatty acid desaturase 1-3) locus and phosphatidylcholines
(PCs) 36:4 and 38:4 (Gieger et al., 2008), as well as between a
variant within GCKR (glucokinase regulator) and alanine (the
GCKR variant was previously associated with alanine/glutamine)
(Kettunen et al., 2012). Novel associations at these loci with tria-
cylglycerol (TAG) traits are discussed further below.
Novel Associations in Directly Related Biological
Pathways
Among the numerous novel findings in our study, we first
describe eight locus-metabolite associations with strong biolog-
ical plausibility. In each case, the locus of interest includes a gene
encoding a protein directly responsible for the metabolism or
transport of the given metabolite. For three of the loci, mutations
have been identified as the cause of human disease. For
example, we identify an association between a variant at
UMPS (uridine monophosphate synthase) and orotic acid.
UMPS encodes an enzyme that combines orotic acid and
ribose-5-phosphate to form uridine monophosphate, and muta-
tions in this gene have been identified as the cause of hereditary
orotic aciduria (OMIM: 258900). Similarly, we identify an associ-
ation between a common variant at AGA (aspartylglucosamini-
dase) and asparagine. AGA encodes an enzyme that cleaves
asparagine fromN-acetylglucosamines as a final step in the lyso-
somal breakdown of glycoproteins, and mutations in this gene
result in the lysosomal storage disease aspartylglycosaminuria
(OMIM: 613228). Finally, we find an association between the
SERPINA7 locus and thyroxine. SERPINA7 encodes thyroxine-
binding globulin, and mutations in this gene result in various de-
grees of thyroxine-binding globulin deficiency (OMIM: 314200).
In addition to these findings with established human disease
correlates, we identify five other locus-metabolite associations
with strong biochemical underpinnings. We find an association
between a variant at DMDGH (dimethylglycine dehydrogenase)
and its enzyme substrate dimethylglycine; at GMPR (guanosine
monophosphate reductase) and the purine nucleoside xantho-
sine; at SLC6A13, which encodes a transporter with known
specificity for g-aminoisobutyrate (GABA), and the GABA-
isomer b-aminoisobutyric acid; at APOA1/C3/A4/A5 (apolipo-
protein A1/C3/A4/A5) and various TAGs and diacylglycerols
(DAGs); and at DDAH1 (dimethylarginine dimethylaminohydro-
lase 1) and NG-monomethylarginine (NMMA). Prior studies
have shown that DDAH1 is responsible for the degradation of
the dimethylarginines NMMA and asymmetric dimethylarginine
(ADMA), but not symmetric dimethylarginine (SDMA) (Hu et al.,
2011), andDDAH1 polymorphisms have previously been associ-ated with ADMA levels (Abhary et al., 2010). In our data, the top
SNP (rs18582) at DDAH1 had a modest association with ADMA
(p = 5.6 3 106), but no association with SDMA (p = 0.15).
Other Novel Locus-Metabolite Associations
Several of the novel locus-metabolite associations identified in
our study include loci without a clear biochemical relationship
with the given metabolite. In several cases, however, these loci
have been associated with human disease or complex disease
phenotypes. For example, mutations inSLC7A9 cause cystinuria
type B (OMIM: 220100) (Feliubadalo´ et al., 1999) and common
variants in SLC7A9 have been associated with chronic kidney
disease (CKD) (Ko¨ttgen et al., 2010). We report an association
between the SLC7A9 locus and NMMA, with the minor allele at
this locus associated with a lower risk of CKD and lower plasma
levels of NMMA, raising the question of whether NMMA is a
potential biomarker or effector of CKD progression. Among the
2076 individuals in the current study, 123 with normal kidney
function at the time of metabolite profiling developed new-onset
CKD in the subsequent 8 years—interestingly, higher plasma
levels of NMMA were significantly associated with the risk of
developing future CKD (OR per SD 1.32, p = 0.003) (Rhee
et al., 2013).
Further examples of locus-metabolite associations identified
in our study with potential links to human disease include an
association between the HPS1 locus (Hermansky-Pudlak syn-
drome 1, OMIM: 203300) and ADMA. Similarly, loci at SYNE2
(spectrin repeat containing, nuclear envelope 2), associated
with sphingomyelin (SM) 14:0 in our data, has been associated
with atrial fibrillation (Ellinor et al., 2012); at DGKB (diacylglycerol
kinase), associated with indole propionate, has been linked to
fasting glucose (Dupuis et al., 2010); at NTAN1 (N-terminal
asparagine amidase), associated with cholesterol ester (CE)
20:3, has been associated with bone mineral density (Estrada
et al., 2012); at LIPC, associated with lysophosphatidylethanol-
amine (LPE) 16:0, has been associated with macular degenera-
tion and themetabolic syndrome (Neale et al., 2010; Kristiansson
et al., 2012); at SLCO1B1 (solute carrier organic anion trans-
porter family member 1B1), associated with LPE 20:4, has
been associated with statin-induced myopathy (Link et al.,
2008); and at PDE4D (phosphodiesterase 4D), associated with
SM 24:1, has previously been linked to stroke (Song et al.,
2006b), although this association was not validated in a larger
study (Bellenguez et al., 2012).
Although we catalog each of the loci that have been associ-
ated with human disease and have at least one genome-wide
significant metabolite association in our study, metabolite
associations that do not reach this threshold may also provide
pathophysiologic insights. As an example, we examined
metabolite associations with variants spanning KCNQ1 (potas-
sium voltage-gated channel, KQT-like subfamily, member 1);
common variants in KCNQ1 have previously been associated
with type 2 diabetes, with the hypothesis that the encoded
channel may modulate pancreatic insulin secretion (Unoki
et al., 2008; Yasuda et al., 2008). In our study, we note an
association between rs384037 in KCNQ1 and triiodothyronine
levels (p = 5.3 3 105). Furthermore, across the 2076
individuals in the current study, triiodothyronine levels are
strongly associated with metabolic traits, including plasmaCell Metabolism 18, 130–143, July 2, 2013 ª2013 Elsevier Inc. 133
Table 2. Genome-wide Significant Loci Associated with Metabolites
Locus Trait SNP ch
Major/
minor Allele MAF Beta s.e. P-value Previous genome-wide associations
AGXT2 b-aminoisobutyric
acid
rs37370 5 T/C 0.10 1.02 0.05 5.8E-83 b-aminoisobutyric acid (Suhre et al., 2011b)
FADS1-3 PC 38:4
PC 36:4
LPC 20:4
CE 20:4
PC 38:5
LPC 20:5
CE 20:5
TAG 58:10
LPE 18:2
TAG 58:11
LPE 20:4
LPC 22:6
PC 34:2
PC 40:6
PC 36:2
PC 34:3
CE 16:0
LPC 20:3
CE 18:3
TAG 54:4
rs174545
rs102275
rs174550
rs174547
rs174535
rs174548
rs174548
rs174548
rs4246215
rs174556
rs174548
rs174550
rs174574
rs174535
rs174541
rs174576
rs174548
rs968567
rs174535
rs174550
11 C/G
T/C
T/C
T/C
T/C
C/G
C/G
C/G
G/T
C/T
C/G
T/C
C/A
T/C
T/C
C/A
C/G
C/T
T/C
T/C
0.33
0.33
0.33
0.33
0.33
0.29
0.29
0.29
0.36
0.29
0.29
0.33
0.33
0.33
0.36
0.33
0.29
0.15
0.33
0.33
0.54
0.45
0.45
0.44
0.41
0.36
0.34
0.30
0.29
0.30
0.30
0.26
0.26
0.26
0.25
0.23
0.23
0.31
0.21
0.19
0.03
0.03
0.03
0.03
0.03
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.05
0.04
0.04
2.7E-61
1.9E-41
9.7E-41
4.7E-37
1.4E-32
1.6E-23
7.8E-21
8.1E-17
2.4E-16
2.5E-16
7.0E-16
1.3E-13
1.3E-13
3.5E-13
2.6E-12
1.7E-10
1.8E-10
4.4E-10
5.5E-09
4.8E-08
Phospholipids (Lemaitre et al., 2011)
Total, HDL, and LDL cholesterol
(Teslovich et al., 2010)
Triglycerides (Teslovich et al., 2010)
Lipid subspecies (Kettunen et al., 2012;
Suhre et al., 2011a)
Fasting glucose (Dupuis et al., 2010)
Crohn’s disease (Franke et al., 2010)
Resting heart rate (Eijgelsheim et al., 2010)
CPS1 Glycine
Creatine
rs7422339
rs7422339
2 C/A
C/A
0.31
0.31
0.53
0.24
0.03
0.04
2.4E-58
2.5E-11
Creatinine production (Ko¨ttgen et al., 2010)
Homocysteine (Lange et al., 2010)
Fibrinogen (Danik et al., 2009)
HPS1 Asymmetric
dimethylarginine
rs6584192 10 T/G 0.37 0.41 0.03 3.5E-33
DMGDH Dimethlyglycine rs248386 5 C/A 0.19 0.50 0.04 6.6E-33
SLC16A9 Carnitine rs1171617 10 T/G 0.23 0.42 0.04 5.9E-26 Carnitine (Suhre et al., 2011a)
Uric acid (Kolz et al., 2009)
SERPINA7 Thyroxine rs7883218 X A/G 0.12 0.39 0.04 1.3E-20
PRODH Proline rs2078743 22 G/A 0.09 0.49 0.06 2.2E-14 Proline (Kettunen et al., 2012)
GMPR Xanthosine rs9477074 6 T/C 0.37 0.25 0.03 3.0E-14 LDL cholesterol (Waterworth et al., 2010)
SLC6A13 b-aminoisobutyric
acid
rs11613331 12 A/G 0.49 0.23 0.03 2.0E-12 Creatinine production (Ko¨ttgen et al., 2010)
LIPC LPE 16:0 rs1532085 15 G/A 0.38 0.24 0.03 3.7E-12 Total and HDL cholesterol (Teslovich et al., 2010)
Triglycerides (Teslovich et al., 2010)
Lipid subspecies (Demirkan et al., 2012;
Gieger et al., 2008; Kettunen et al., 2012)
Metabolic syndrome (Kristiansson et al., 2012)
Macular degeneration (Neale et al., 2010)
GCKR Alanine
Lactate
a-hydroxybutyrate
TAG 50:4
TAG 48:2
TAG 50:3
PC 34:3
PC 32:2
TAG 48:3
rs1260326
rs1260326
rs1260326
rs1260326
rs1260326
rs1260326
rs1260326
rs1260326
rs1260326
2 C/T
C/T
C/T
C/T
C/T
C/T
C/T
C/T
C/T
0.45
0.45
0.45
0.45
0.45
0.45
0.45
0.45
0.45
0.23
0.24
0.22
0.20
0.19
0.19
0.18
0.19
0.18
0.03
0.04
0.04
0.03
0.03
0.03
0.03
0.03
0.03
7.6E-12
3.3E-11
1.3E-09
3.4E-09
2.5E-08
2.6E-08
2.9E-08
3.9E-08
4.9E-08
Triglycerides (Teslovich et al., 2010)
Total cholesterol (Teslovich et al., 2010)
Phospholipids (Demirkan et al., 2012;
Lemaitre et al., 2011)
CRP (Dehghan et al., 2011; Ridker et al., 2008)
Chronic kidney disease (Ko¨ttgen et al., 2010)
Glycemic traits (Dupuis et al., 2010;
Saxena et al., 2010)
Uric acid (Kolz et al., 2009; Yang et al., 2010)
Alanine/glycine (Kettunen et al., 2012)
Platelet count (Gieger et al., 2011)
Albumin (Kamatani et al., 2010; Kim et al., 2011)
Glucose/mannose (Suhre et al., 2011a)
Crohn’s disease (Franke et al., 2010)
(Continued on next page)
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Table 2. Continued
Locus Trait SNP ch
Major/
minor Allele MAF Beta s.e. P-value Previous genome-wide associations
APOA1/
C3/A4/A5
DAG 36:2
TAG 56:3
TAG 56:10
TAG 54:2
TAG 52:4
TAG 54:3
DAG 34:2
TAG 52:5
DAG 36:1
TAG 52:3
TAG 54:5
rs964184
rs964184
rs964184
rs964184
rs964184
rs964184
rs964184
rs964184
rs964184
rs12294259
rs964184
11 C/G
C/G
C/G
C/G
C/G
C/G
C/G
C/G
C/G
C/T
C/G
0.14
0.14
0.14
0.14
0.14
0.14
0.14
0.14
0.14
0.06
0.14
0.33
0.32
0.31
0.31
0.30
0.29
0.28
0.28
0.28
0.39
0.26
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.07
0.05
1.3E-11
2.8E-11
1.5E-10
1.9E-10
2.4E-10
3.2E-09
6.0E-09
7.4E-09
8.2E-09
1.7E-08
4.8E-08
Triglycerides (Teslovich et al., 2010)
HDL cholesterol (Teslovich et al., 2010)
Coronary artery disease (Schunkert et al., 2011)
DDAH1 NG-monomethyl-
arginine
rs18582 1 A/G 0.35 0.24 0.04 2.2E-11
SLCO1B1 LPE 20:4 rs4149056 12 T/C 0.15 0.30 0.05 1.1E-10 Bilirubin (Johnson et al., 2009)
Statin-induced myopathy (Link et al., 2008)
Lipid subspecies (Suhre et al., 2011a)
AGA Asparagine rs4690522 4 C/A 0.32 0.25 0.04 1.4E-10
SYNE2 SM 14:0 rs11158519 14 G/A 0.14 0.31 0.05 3.2E-10 Lipid subspecies (Illig et al., 2010)
Atrial fibrillation (Ellinor et al., 2012)
Pulmonary function decline (Imboden et al., 2012)
UMPS Orotic acid rs9844948 3 C/A 0.16 0.32 0.05 7.6E-10
PDE4D SM 24:1 rs4700347 5 A/G 0.16 0.28 0.05 3.4E-09 Stroke (Song et al., 2006b)
Esophageal cancer (Wu et al., 2011)
Asthma (Himes et al., 2009)
Sleepiness (Gottlieb et al., 2007)
SEC61G CE 20:4 rs11981543 7 C/A 0.11 0.32 0.05 4.2E-09
rs6593086 TAG 58:9
TAG 56:7
TAG 58:8
rs6593086
rs6593086
rs6593086
7 C/G
C/G
C/G
0.34
0.34
0.34
0.20
0.20
0.20
0.03
0.03
0.03
4.4E-09
6.1E-09
2.0E-08
UGT1A5 Xanthurenate rs4148325 2 C/T 0.31 0.23 0.04 4.9E-09 Bilirubin (Johnson et al., 2009; Sanna et al., 2009)
SLC7A9 NG-monomethyl-
arginine
rs8101881 19 T/C 0.44 0.20 0.03 5.0E-09 Chronic kidney disease (Ko¨ttgen et al., 2010)
Creatinine level (Chambers et al., 2010)
Urine lysine/valine (Suhre et al., 2011b)
ABP1 g-aminoisobutyric
acid
rs6977081 7 G/T 0.34 0.23 0.04 5.4E-09
PHGDH Serine rs477992 1 G/A 0.32 0.21 0.04 6.5E-09 Serine (Suhre et al., 2011a)
SLC16A10 Tyrosine rs411604 6 G/A 0.36 0.20 0.04 1.0E-08 Isoleucine/Tyrosine (Suhre et al., 2011a)
Alanine/Tyrosine (Kettunen et al., 2012)
CSNK1G3 Indoxyl sulfate rs875480 5 A/G 0.24 0.25 0.04 1.4E-08
GNAL CE16:0 rs1786573 18 T/C 0.27 0.21 0.04 2.8E-08
DGKB Indole propionate rs12699655 7 T/G 0.45 0.21 0.04 3.1E-08 Glycemic traits (Dupuis et al., 2010)
TBX18 DAG 36:1 rs4510639 6 C/T 0.25 0.21 0.04 3.5E-08
NTAN1 CE 20:3 rs3803573 16 C/T 0.28 0.21 0.04 4.7E-08 Bone mineral density (Estrada et al., 2012)
Thirty-one genetic loci with at least one genome-wide significant metabolite association are shown. Citations are provided for previously established
associations between these loci and other traits. SNP, single nucleotide polymorphism; MAF, minor allele frequency; ch, chromosome; s.e., standard
error; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; CE, cholesterol ester; TAG, triacylglycerol; LPE, lysophosphatidylethanolamine; DAG,
diacylglycerol; SM, sphingomyelin. See also Figures S2 and S3 and Tables S2 and S3.
Cell Metabolism
Metabolomics GWAS in the FHSinsulin levels (p = 1.5 3 1020), plasma triglyceride levels (p =
5.3 3 1012), and body-mass index (p = 4.9 3 108). Thus,
our data in FHS raise the possibility that the association
between common variants in KCNQ1 and type 2 diabetes
may also be mediated by the gene’s role in modulating plasma
triiodothyronine levels.Lipid Profiling Demonstrates Heterogeneous Effects of
Loci Associated with Total Triglycerides
Although prior GWAS have identified numerous loci associated
with total triglyceride levels, our study is the first to incorporate
comprehensive TAG profiling. As various combinations of
acyl chains may be esterified to a glycerol backbone, bulkCell Metabolism 18, 130–143, July 2, 2013 ª2013 Elsevier Inc. 135
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Figure 2. Thirty-One Genome-wide Significant Loci Associated with Metabolites in FHS
Loci with significant metabolite associations in FHS are depicted within the black circle. Overlap with prior studies (dotted circles) is indicated for eight loci. Prior
studies found an association between common variants at *AGXT2 and urinary levels of b-aminoisobutyric acid, yGCKR and the alanine/glutamine ratio,
and zSLC16A10 and the tyrosine/isoleucine and alanine/tyrosine ratios. See also Figures S2 and S3.
Cell Metabolism
Metabolomics GWAS in the FHStriglycerides are actually composed of dozens of distinct TAG
molecules. In the current study, we identify significant TAG asso-
ciations for three loci previously associated with total triglycer-
ides: GCKR, and the FADS1-3 and APOA1/C3/A4/A5 gene
clusters. A fourth region at chromosome 7p12.1 (rs6593086)
found to be associated with TAG traits has not been previously
associated with total triglyceride levels. To test the hypothesis
that the higher-resolution phenotyping enabled by our platform
sheds insight on these associations, we examined each locus’s
association with all of the TAGs monitored by our platform.
For leading SNPs at GCKR, FADS1-3, APOA1/C3/A4/A5, and
rs6593086, Figure 3 depicts the beta coefficient and P value for
association across the 46 TAGsmeasured in FHS. As suggested
by the four significant findings (TAGs 48:2, 48:3, 50:3, 50:4), the
GCKR locus demonstrated a stronger association with TAGs of
relatively lower carbon content (Figure 3A). A comprehensive
view of PCs shows a similar pattern of association (including sig-
nificant associations with PC 32:2 and PC34:3) (Figure 4A).
Notably, the top SNP associated with these metabolic traits
was rs1260326, a missense variant (L446P) that in functional
studies has been established as the likely causal variant explain-
ing the association with fasting bulk triglyceride and glucose
levels (Beer et al., 2009; Orho-Melander et al., 2008).
In contrast to the GCKR locus, the FADS1-3 locus had stron-
ger associations with TAGs of relatively higher carbon and dou-136 Cell Metabolism 18, 130–143, July 2, 2013 ª2013 Elsevier Inc.ble bond content (Figure 3B), including significant associations
with TAGs 54:4, 58:10, and 58:11. These data extend prior
work that has demonstrated a similar pattern of association
between this locus and plasma phospholipid carbon and double
bond content (Gieger et al., 2008), and is corroborated by our
own PC data (Figure 4B). The leading SNP in the APOA1/C3/
A4/A5 gene cluster was associated with an intermediate TAG
phenotype relative toGCKR and FADS1-3, demonstrating stron-
ger associations for TAGs with intermediate carbon content
(Figure 3C; i.e., TAGs with 50 to 56 carbons). Figure 3D demon-
strates a striking pattern of TAG associations for rs6593086, a
SNP that is located >50 kb from the closest coding gene
(POM121L12). As with the FADS1-3 locus, this SNP had stronger
associations with TAGs of relatively greater carbon and double
bond content, although the significant associations were
nonoverlapping. Further, rs6593086 had a consistent direction
of association across themajority of TAGs, whereas the direction
of effect for the FADS1-3 locus differed at the extremes of TAG
carbon content.
Genome-wide Association Data across All Surveyed
Metabolites as a Resource for Metabolism Research
Although the novelty of our TAG data set motivates interest in
select TAG association patterns, further interrogation of the
breadth of our data will provide other insights as well. To that
P
-value
P
-value
1.E-09
1.E-07
1.E-05
1.E-03
1.E-01
-0.10
-0.05
0.00
0.05
0.10
0.15
0.20
0.25
TA
G
 4
4:
1
TA
G
 4
6:
2
TA
G
 4
6:
1
TA
G
 4
6:
0
TA
G
 4
8:
4
TA
G
 4
8:
3
TA
G
 4
8:
2
TA
G
 4
8:
1
TA
G
 4
8:
0
TA
G
 5
0:
5
TA
G
 5
0:
4
TA
G
 5
0:
3
TA
G
 5
0:
2
TA
G
 5
0:
1
TA
G
 5
2:
6
TA
G
 5
2:
5
TA
G
 5
2:
4
TA
G
 5
2:
3
TA
G
 5
2:
2
TA
G
 5
2:
1
TA
G
 5
4:
9
TA
G
 5
4:
8
TA
G
 5
4:
7
TA
G
 5
4:
6
TA
G
 5
4:
5
TA
G
 5
4:
4
TA
G
 5
4:
3
TA
G
 5
4:
2
TA
G
 5
4:
1
TA
G
 5
6:
10
TA
G
 5
6:
9
TA
G
 5
6:
8
TA
G
 5
6:
7
TA
G
 5
6:
6
TA
G
 5
6:
5
TA
G
 5
6:
4
TA
G
 5
6:
3
TA
G
 5
6:
2
TA
G
 5
8:
12
TA
G
 5
8:
11
TA
G
 5
8:
10
TA
G
 5
8:
9
TA
G
 5
8:
8
TA
G
 5
8:
7
TA
G
 5
8:
6
TA
G
 6
0:
12
1.E-16
1.E-14
1.E-12
1.E-10
1.E-08
1.E-06
1.E-04
1.E-02
1.E+00-0.40
-0.30
-0.20
-0.10
0.00
0.10
0.20
0.30
TA
G
 4
4:
1
TA
G
 4
6:
2
TA
G
 4
6:
1
TA
G
 4
6:
0
TA
G
 4
8:
4
TA
G
 4
8:
3
TA
G
 4
8:
2
TA
G
 4
8:
1
TA
G
 4
8:
0
TA
G
 5
0:
5
TA
G
 5
0:
4
TA
G
 5
0:
3
TA
G
 5
0:
2
TA
G
 5
0:
1
TA
G
 5
2:
6
TA
G
 5
2:
5
TA
G
 5
2:
4
TA
G
 5
2:
3
TA
G
 5
2:
2
TA
G
 5
2:
1
TA
G
 5
4:
9
TA
G
 5
4:
8
TA
G
 5
4:
7
TA
G
 5
4:
6
TA
G
 5
4:
5
TA
G
 5
4:
4
TA
G
 5
4:
3
TA
G
 5
4:
2
TA
G
 5
4:
1
TA
G
 5
6:
10
TA
G
 5
6:
9
TA
G
 5
6:
8
TA
G
 5
6:
7
TA
G
 5
6:
6
TA
G
 5
6:
5
TA
G
 5
6:
4
TA
G
 5
6:
3
TA
G
 5
6:
2
TA
G
 5
8:
12
TA
G
 5
8:
11
TA
G
 5
8:
10
TA
G
 5
8:
9
TA
G
 5
8:
8
TA
G
 5
8:
7
TA
G
 5
8:
6
TA
G
 6
0:
12
FADS1-3
GCKR
A
B
C 1.E-11
1.E-09
0.25
0.30
0.35 APOA1/C3/A4/A5
B
et
a
B
et
a
P
-value
P
-value
D
1.E-07
1.E-05
1.E-03
1.E-01
-0.05
0.00
0.05
0.10
0.15
0.20
TA
G
 4
4:
1
TA
G
 4
6:
2
TA
G
 4
6:
1
TA
G
 4
6:
0
TA
G
 4
8:
4
TA
G
 4
8:
3
TA
G
 4
8:
2
TA
G
 4
8:
1
TA
G
 4
8:
0
TA
G
 5
0:
5
TA
G
 5
0:
4
TA
G
 5
0:
3
TA
G
 5
0:
2
TA
G
 5
0:
1
TA
G
 5
2:
6
TA
G
 5
2:
5
TA
G
 5
2:
4
TA
G
 5
2:
3
TA
G
 5
2:
2
TA
G
 5
2:
1
TA
G
 5
4:
9
TA
G
 5
4:
8
TA
G
 5
4:
7
TA
G
 5
4:
6
TA
G
 5
4:
5
TA
G
 5
4:
4
TA
G
 5
4:
3
TA
G
 5
4:
2
TA
G
 5
4:
1
TA
G
 5
6:
10
TA
G
 5
6:
9
TA
G
 5
6:
8
TA
G
 5
6:
7
TA
G
 5
6:
6
TA
G
 5
6:
5
TA
G
 5
6:
4
TA
G
 5
6:
3
TA
G
 5
6:
2
TA
G
 5
8:
12
TA
G
 5
8:
11
TA
G
 5
8:
10
TA
G
 5
8:
9
TA
G
 5
8:
8
TA
G
 5
8:
7
TA
G
 5
8:
6
TA
G
 6
0:
12
1.E-09
1.E-07
1.E-05
1.E-03
1.E-01
-0.25
-0.20
-0.15
-0.10
-0.05
0.00
0.05
0.10
TA
G
 4
4:
1
TA
G
 4
6:
2
TA
G
 4
6:
1
TA
G
 4
6:
0
TA
G
 4
8:
4
TA
G
 4
8:
3
TA
G
 4
8:
2
TA
G
 4
8:
1
TA
G
 4
8:
0
TA
G
 5
0:
5
TA
G
 5
0:
4
TA
G
 5
0:
3
TA
G
 5
0:
2
TA
G
 5
0:
1
TA
G
 5
2:
6
TA
G
 5
2:
5
TA
G
 5
2:
4
TA
G
 5
2:
3
TA
G
 5
2:
2
TA
G
 5
2:
1
TA
G
 5
4:
9
TA
G
 5
4:
8
TA
G
 5
4:
7
TA
G
 5
4:
6
TA
G
 5
4:
5
TA
G
 5
4:
4
TA
G
 5
4:
3
TA
G
 5
4:
2
TA
G
 5
4:
1
TA
G
 5
6:
10
TA
G
 5
6:
9
TA
G
 5
6:
8
TA
G
 5
6:
7
TA
G
 5
6:
6
TA
G
 5
6:
5
TA
G
 5
6:
4
TA
G
 5
6:
3
TA
G
 5
6:
2
TA
G
 5
8:
12
TA
G
 5
8:
11
TA
G
 5
8:
10
TA
G
 5
8:
9
TA
G
 5
8:
8
TA
G
 5
8:
7
TA
G
 5
8:
6
TA
G
 6
0:
12
rs6593086
B
et
a
B
et
a
Figure 3. Metabolite Profiling Demonstrates
Distinct Patterns of TAG Associations for
Select Loci
(A–D) For the 46 triacylglycerols (TAGs) monitored
by our platform, the beta coefficient (left y axis) and
P value (right y axis) of association are shown for the
top variant at (A)GCKR, (B) FADS1-3, (C) APOA1/C3/
A4/A5, and (D) rs6593086.
Cell Metabolism
Metabolomics GWAS in the FHSend, we include GWAS data for each of the 217 metabolites
surveyed by our platform, including all loci with p < 1.0 3 103
(Table S2), as well as comprehensive metabolite data for each
locus with at least one genome-wide significant association
(Table S3). With these resources, we believe that independent
investigators will be able to rapidly interrogate the genetic
underpinnings of metabolites of interest, including biologically
meaningful associations that do not meet the genome-wide sig-
nificance threshold (but potentially of high statistical significance
in a focused interrogation). Conversely, investigators focused on
a particular gene highlighted by our study will be able to query
which metabolites are downstream of common genetic variationCell Metabolism 18, 1in that gene. Finally, access to the breadth
of our metabolite GWAS data will com-
plement the publicly available metabolite
data that we have already uploaded on the
database of Genotypes and Phenotypes
(http://www.ncbi.nlm.nih.gov/gap) for all
2076 individuals in FHS profiled in the
current study.
To provide proof of principle of this
approach, we examined our data in the
FHS on b-aminoisobutyric acid. In cross-
sectional analyses, plasma b-aminoisobuty-
ric acid levels have a negative correlation
with serum triglyceride levels in the FHS
(a 1-SD decrement in log b-aminoisobutyric
acid is associated with a 1.07 mg/dL in-
crease in serum triglyercides, p = 2.3 3
1021). In the current study, we identify a
striking association between the AGXT2
locus and plasma b-aminoisobutyric acid
levels (p = 5.8 3 1083), with the top
SNP (rs37370) in AGXT2 accounting for
36% of its estimated heritability. In light of
the cross-sectional association between
b-aminoisobutyric acid levels and total
triglycerides, we were interested to note
that rs37370 also had many nominal associ-
ations with plasma TAGs and CEs (Table
S4), with the direction of association oppo-
site for TAGs versus CEs, suggesting that
genes responsible for b-aminoisobutyric
acid metabolism may have a causal and
opposing impact on plasma TAG and CE
levels.
In order to test this potential link between
b-aminoisobutyric acid and lipid homeosta-
sis, we knocked down agxt2 in zebrafishusing morpholino antisense oligonucleotides (Figures S4A and
S4B). In some fish, this knockdown resulted in no overt pheno-
type, whereas in others it resulted in a prominent defect in yolk
sack extension and mild pericardial edema (Figure 5A). When
compared to control fish, agxt2 knockdown fish with normal
phenotype (AGXT2 I) and abnormal phenotype (AGXT2 II) had
lower agxt2mRNA (Figure 5B) and b-aminoisobutyric acid levels
(Figure 5C); further, AGXT2 II fish had a trend for lower agxt2
mRNA and b-aminoisobutyric acid levels compared to AGXT2 I
fish. Lipid profiling demonstrated a broad, opposing, and
dose-dependent impact of agxt2 knockdown on fish CE and
TAG levels (Figures 5D and 5E) that aligns with the opposing30–143, July 2, 2013 ª2013 Elsevier Inc. 137
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Figure 4. Phosphatidylcholine associations for the GCKR and
FADS1-3 loci
(A and B) For the 18 phosphatidylcholines (PCs) monitored by our platform, the
beta coefficient (left y axis) and P value (right y axis) of association are shown
for the top variant at (A) GCKR and (B) FADS1-3.
Cell Metabolism
Metabolomics GWAS in the FHSdirectionality of association between the AGXT2 locus and TAG
and CE levels in humans (Figure 5F).
To test whether the association between b-aminoisobutyric
acid and lipid metabolism is specific to agxt2, we used morpho-
lino antisense oligonucleotides to knock down abat (Figure S4C),
which encodes an enzyme that catalyzes an alternative pathway
for b-aminoisobutyric acid metabolism (Figure S4A). As with
agxt2 knockdown, abat knockdown resulted in an abnormal
phenotype notable for a defect in yolk sack extension and
pericardial edema (Figure S4D). Furthermore, abat knockdown
in fish resulted in decreased b-aminoisobutyric acid levels
compared to control fish (Figure S4E) and recapitulated the
decrease in CE levels and the increase in TAG levels seen in
agxt2 knockdown fish (Figures S4F and S4G).
Because cholesterol esterification is confined to a defined set
of enzymes, encoded by lcat, soat1, and soat2, we next as-
sessed the effect of agxt2 and abat knockdown in zebrafish on
the expression of these genes (Figure S5). We found that both
agxt2 and abat knockdown resulted in decreased expression
of lcat and soat2, consistent with the lower CE levels identified
by LC-MS. Notably, humans with inherited LCAT deficiency
develop both marked reductions in circulating CE levels as well
as hypertriglyceridemia (Frohlich et al., 1988). Lcat ablation in
mice similarly results in hypertriglyceridemia, whereas trans-
genic Lcat overexpression results in lower plasma triglyceride
levels (Ng et al., 1997; Francone et al., 1995). Although the exact
molecular pathways linking CE and TAG metabolism in these138 Cell Metabolism 18, 130–143, July 2, 2013 ª2013 Elsevier Inc.contexts have not been fully elucidated, Ng et al. have shown
that Lcat deficiency in mice results in (1) increased triglyceride
production, with increased expression of Srebp-1, Fas, and
Acc-1; (2.) decreased triglyceride catabolism, with impaired
lipase activity; and (3) increased expression of Hmgcr and
decreased expression of Soat2 (Ng et al., 2004; Song et al.,
2006a). In addition to lowering the expression of lcat and
soat2, we found that both agxt2 and abat knockdown in zebrafish
resulted in increased expression of srebp-1 and hmgcr, as well
as decreased expression of lipc (Figure S5). Taken together,
these data extend the results of gene-metabolite-phenotype
data in FHS and highlight a functional link between b-aminoiso-
butyric acid, CE, and TAG metabolism in zebrafish.
DISCUSSION
Our platform surveys >100 metabolites not screened in prior
GWAS, and extends recent efforts to annotate the common
genetic determinants of circulating metabolite levels. Previously
unmeasured metabolites include several distinct classes of
lipid analytes for which we report numerous locus-metabolite
associations, many in loci previously associated with human
disease. Furthermore, using the rigorous characterization of
clinical factors and family-based relationships of FHS partici-
pants, we delineate the relative contributions of inherited, envi-
ronmental, and clinical factors on the metabolome. For select
loci, we show that a broad view of metabolite associations pro-
vides insight on gene function, in some cases confirming known
biochemical functions of the gene product (e.g., FADS1-3) and in
others highlighting unanticipated metabolic roles (e.g., AGXT2).
For the majority of analytes, variation attributable to heritable
factors is greater than that attributable to clinical factors, with
the notable exception of the tobacco metabolite cotinine. In
fact, heritability estimates for manymetabolites are considerably
higher than for traditional biomarkers, such as B-type natriuretic
peptide (h2 = 0.35) (Wang et al., 2003) or C-reactive protein (h2 =
0.30) (Schnabel et al., 2009). In some cases, this highlights
metabolites that serve as proximal reporters of underlying
gene function. For example, the top SNP (rs37370) in AGXT2
accounts for approximately a third of the estimated heritability
for its enzyme substrate b-aminoisobutyric acid. The top
SNPs for glycine (rs7422339, CPS1) and PCs 36:4 and 38:4
(rs102275, FADS1-3) account for nearly all of their heritability
(Figure 1). For most metabolites, however, either no genome-
wide significant association was identified or the top genome-
wide significant SNP explained only a small fraction of overall
heritability. To what extent the unexplained heritability for
these metabolites is attributable to common polymorphisms
with subgenome wide associations, the effect of rare variants
or copy number variants not captured by SNPs in GWAS arrays,
or other factors (including shared environmental factors) remains
undetermined.
For select loci associated with human disease, e.g., UMTS
and hereditary orotic aciduria, the locus-metabolite association
identified in our study reflects the gene product’s enzymatic
function. By contrast, several loci with previously established
disease associations have no enzymatic or transport function
directly related to the associated metabolite. In these cases,
the locus-metabolite association identified in our study may
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Figure 5. AGXT2 Modulates Lipid Homeostasis in Zebrafish
(A) Zebrafish embryos were injected with 2 nL of a 400 mMsolution of a splice blocking agxt2morpholino oligonucleotide (MO) or control MO. At 48 hpf, agxt2MO
injection resulted in morphants with both normal phenotype (upper right panel, ‘‘AGXT2 I’’) and morphants with defective yolk sac extension and pericardial
edema (lower left panel, ‘‘AGXT2 II’’).
(B) RT-PCR of agxt2mRNA for control, AGXT2 I and AGXT2 II morphants at 48 hpf; the 300 nucleotide fragment is theWT agxt2 transcript and the 109 nucleotide
fragment is the knocked-down (KD) agxt2 transcript. The relative extent of WT agxt2 expression, normalized to rpl13-a, was estimated from band intensities; data
are presented as mean ± SD, *p < 0.05 for comparison to control.
(C) b-aminoisobutyric acid levels in control, AGXT2 I and AGXT2 II morphants at 48 hpf; data are presented as mean ± SD, *p < 0.05 for comparison to control.
(D and E) CE (D) and TAG (E) levels for control, AGXT2 I and AGXT II larvae at 5 dpf; data are presented asmean ± SD, *p < 0.05 for comparison to control, #p < 0.05
for comparison to AGXT2 I.
(F) For TAGs (solid circles) and CEs (hollow circles), plot of eachmetabolite’s association with rs37370 (AGXT2) in FHS on the x axis versus the percent difference
for each metabolite in AGXT I versus control zebrafish on the y axis. See also Figures S4 and S5 and Table S4.
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Metabolomics GWAS in the FHSprovide information on the pathophysiologic link between a
given locus and disease (Adamski, 2012; Suhre and Gieger,
2012). For example, the SLC7A9 locus, associated with NMMA
in our study, encodes an amino acid transporter in the kidney
with specificity for dibasic amino acids including cystine and
arginine (Mora et al., 1996). Common variants in SLC7A9 have
been associated with CKD (Ko¨ttgen et al., 2010). However,
CKD is not characterized by cystinuria or cystine stones, as
with the Mendelian disorder attributable to SLC7A9 mutations.
Our data highlight plasma NMMA, a methylarginine that inhibits
NO synthase (Vallance et al., 1992) as a potential intermediary
between common variation at this locus and renal disease.
Indeed, we find that elevated plasma levels of NMMA are asso-
ciated with an increased risk of future CKD among individuals
with normal kidney function at baseline. Thus, our data raisethe hypothesis that NMMA could be both a biomarker and
effector of CKD risk.
Because a narrow focus on only genome-wide significant
associations is likely to overlook biologically meaningful findings,
we also highlight a sub-genome-wide significant association
between KCNQ1, previously associated with type 2 diabetes,
and triiodothyronine levels. Notably, recent studies demonstrate
an essential role for the KCNQ1 channel in thyroid I uptake
(Purtell et al., 2012). Further, Kcnq1 ablation in mice has been
shown to result in hypothyroidism (Fro¨hlich et al., 2011). In
cross-sectional analyses, we find that plasma triiodothyronine
levels are strongly correlated with metabolic parameters in
FHS, including plasma insulin, plasma triglycerides, and BMI.
Thus, in addition to raising an intriguing link between potassium
channel function in the thyroid and type 2 diabetes risk, theseCell Metabolism 18, 130–143, July 2, 2013 ª2013 Elsevier Inc. 139
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Metabolomics GWAS in the FHSfindings reinforce the potential value of the full breadth and depth
of our data.
We also show that a more granular lipidomic analysis informs
findings from prior GWAS of bulk lipid measures. More specif-
ically, we examine the association across all TAGs for select
loci and identify distinct TAG signatures that highlight underlying
gene function. The FADS1-3 locus had a strong association with
TAGs of high double-bond content, as would be expected given
the critical role the fatty acid desaturases encoded at this locus
play in the synthesis of u-3 and u-6 polyunsaturated fatty acids.
By contrast, the GCKR locus had a stronger association for
TAGs of lower carbon and double-bond content. We and others
have previously shown that these TAGs are tightly correlated
with insulin resistance, whereas TAGs with relatively higher car-
bon (and double-bond) content are associated with increased
insulin sensitivity (Kotronen et al., 2009; Rhee et al., 2011). The
APOA1/C3/A4/A5 locus was associated with TAGs of intermedi-
ate carbon content. Unlike TAGs at the lower and higher ex-
tremes of carbon content, these TAGs are comprised primarily
of the abundant fatty acids palmitic acid, palmitoleic acid, stearic
acid, and oleic acid, and as a result make the largest quantitative
contribution to total plasma triglyceride levels (i.e., plasma
lipoprotein triglyceride content) (Rhee et al., 2011). Finally,
rs6593086 demonstrated a striking pattern of TAG associa-
tion—although no coding gene resides within 50 kb of this
SNP, our data predicts a role for this genomic region in the regu-
lation of fatty acid desaturation and/or elongation.
In order to further demonstrate how a metabolomic approach
is able to elucidate new biology, we tested the effects of agxt2
and abat knockdown in zebrafish. Because cross-sectional ana-
lyses highlighted a strong correlation between b-aminoisobuty-
ric acid levels and total triglycerides in the FHS, and because
the AGXT2 locus (a powerful determinant of b-aminoisobutyric
acid levels) also had nominal associations with plasma TAGs
and CEs, we hypothesized that modulating agxt2 would impact
b-aminoisobutyric acid levels and modulate lipid homeostasis
in fish. Indeed, we noted a dose-dependent increase in TAGs
and decrease in CEs following gene knockdown. Similar ex-
periments using abat knockdown resulted in a similar decre-
ment in b-aminoisobutyric acid levels and recapitulated the
increase in TAGs and decrease in CEs observed with agxt2
knockdown. Both agxt2 and abat knockdown resulted in
decreased lcat and soat2 expression, increased srebp-1 expres-
sion, and decreased lipc expression, all findings that would be
expected to result in the decreased CE and increased TAG levels
observed in these fish. Although further studies are needed to
understand howmodulating b-aminoisobutyric acid, a catabolite
of thymine and valine, impacts the expression of lcat, srebp-1,
and other fundamental effectors of lipid metabolism, our data
provide an example of how the breadth of gene, metabolite,
and phenotype data we present in the FHS can provide a spring-
board for research in metabolism.
Because our platform measures numerous metabolites not
surveyed in prior metabolomics GWAS, additional profiling in
other cohorts will be required to validate our findings. However,
we note that our study does recapitulate eight locus-metabolite
associations reported in prior metabolomics GWAS. Further,
eight of our novel findings highlight loci encoding enzymes
or transporters directly linked to the associated metabolite,140 Cell Metabolism 18, 130–143, July 2, 2013 ª2013 Elsevier Inc.providing internal validation by way of biological plausibility.
Nevertheless, future efforts will seek to provide external replica-
tion for several of the associations identified in this study. As the
FHS includes middle-aged-to-older individuals of predominantly
European ancestry, future studies should also include more
diverse populations in order to test the generalizability of our
findings.
In summary, we performed a metabolomics GWAS on plasma
obtained from 2076 individuals in a large, community-based
cohort. This study corroborates prior data demonstrating the
relatively high heritability estimates for circulating metabolites,
and it is the first to compare these measures against the
contribution of clinical covariates. Further, we report 31 loci
with significant metabolite associations and show how exam-
ining association patterns across the metabolome for select
loci may begin to provide insights in metabolism. Importantly,
we include GWAS data on all metabolites surveyed, as well as
full metabolite data for each locus with at least one significant
association, as a resource for the scientific community. We
anticipate that future efforts to understand and synthesize sub-
genome-wide significant findings and to understand patterns
of metabolite associations will further elucidate the genetic
determinants of the plasma metabolome and provide new in-
sights about gene function and disease pathogenesis in the
context of human metabolism.
EXPERIMENTAL PROCEDURES
Study Sample
The FHS Offspring cohort is a prospective, observational, community-based
cohort (Kannel et al., 1979). The children of FHS participants and their spouses
were recruited in 1971 and have been followed with serial examinations. A total
of 2076 participants of European descent who attended the fifth examination
(1991–1995) and underwent metabolic profiling and genome-wide genotyping
were included in this analysis. All participants provided informed consent and
the study protocol was approved by the Boston UniversityMedical Center IRB.
Clinical Assessment
Participants underwent a comprehensive medical history, physical examina-
tion, and anthropormetry at the fifth examination. Diabetes mellitus was
defined as a fasting glucose R126 mg/dL, nonfasting blood glucose
R200mg/dL, or the use of insulin or oral antidiabetic medications. Participants
who had smoked regularly during the prior year were considered current
smokers. Fasting total and high-density lipoprotein cholesterol levels were
obtained. Estimated glomerular filtration rate (eGFR) was calculated using
theModification of Diet in Renal Disease equation (Levey et al., 1999). Previous
cardiovascular events were adjudicated by a 3-physician panel after review of
medical records, and included a history of coronary heart disease, heart
failure, and stroke.
Genome-wide Genotyping and Imputation
Genotyping methods have previously been described (Wilk et al., 2009). In
brief, genome-wide genotyping was conducted using the Affymetrix 500K
mapping array and the Affymetrix 50K gene-focused MIP array. Genotypes
were called using Chiamo (http://www.stats.ox.ac.uk/marchini/software/
gwas/chiamo.html). Imputation of 2.5 million SNPs was then performed
(HapMap CEU population, release 22, build 36; http://hapmap.org) using a
hidden Markov model that was implemented in MACH (version 1.0.15) (Li
et al., 2010).
Metabolite Profiling
Blood sampleswere collected after an overnight fast, immediately centrifuged,
and stored at 80C until assayed. Amino acids, amino acid derivatives,
urea cycle intermediates, nucleotides, and other positively charged polar
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Metabolomics GWAS in the FHSmetabolites were profiled as previously described using 10 ml of plasma (Wang
et al., 2011). Lipids were profiled as previously described using 10 ml of plasma
(Rhee et al., 2011). For each lipid analyte, the first number denotes the total
number of carbons in the lipid acyl chain(s), and the second number (after
the colon) denotes the total number of double bonds in the lipid acyl chain(s).
For organic acids, sugars, bile acids, and other negatively charged polar
metabolites, 30 ml of plasma were used and MS data were acquired using
ESI and MRM in the negative ion mode (details provided in the Supplemental
Experimental Procedures). Table S5 lists the 217metabolites measured by our
platform and specifies overlap with prior metabolomics-GWAS.
Statistical Analysis
The percent interindividual variability in log-transformed metabolite concen-
trations accounted for by measured clinical factors (R2) was assessed using
multivariable linear regression models adjusted for age, sex, systolic blood
pressure, antihypertensive medication use, body-mass index, diabetes,
smoking status, and prevalent cardiovascular disease. In secondary analyses,
we further adjusted for eGFR. Analyses were performed using SAS, version
9.1.3 (SAS Institute, Cary, NC, USA).
Due to right-skewed distributions of metabolite levels and differences in
scaling, genetic analyses were conducted using normalized residuals of
metabolite levels, adjusted for age and sex. Heritability of each metabolite
was estimated using variance-component models and Sequential Oligogenic
Linkage Analysis Routines (SOLAR) (Almasy and Blangero, 1998). The associ-
ation of genetic variants andmetabolite concentrations was tested using linear
mixed effects models to accommodate pedigree data under an additive
genetic model. Genome-wide association analyses were performed using R
(Chen and Yang, 2010), and implemented using the lmekin function in the
kinship package (Therneau et al., 2003). Population stratification was
accounted for by adjusting for PC1 if p < 0.0001, and the final genomic control
parameter lambda was < 1.03 for all analyses. Results were filtered for minor
allele frequency > 5% and imputation ratio of >0.80. Results were considered
genome-wide significant at p < 5.0 3 108.
Zebrafish Studies
All zebrafish studies were approved by the MGH Subcommittee on Research
Animal Care. The splice blocking agxt2 and abat morpholino oligonucleotides
(MOs) were designed to target the intron1-exon2 junction and the intron4-
exon5 junction (Figure S4) in agxt2 and abat, respectively (Gene Tools, LLC),
and were injected into one- to two-cell stage zebrafish embryos using an
Eppendorf Femtojet microinjector. Forty-eight hours post fertilization, em-
bryos were utilized for b-aminoisobutyric acid measurement, and 5 days
post fertilization larvae were used for CE- and TAG-related gene expression
and lipid profiling. Metabolite and gene-expression data were compared
across groups using two-tailed t tests.
ACCESSION NUMBERS
The following accession numbers have been uploaded on the Genotypes and
Phenotypes database: pht002234.v3.p7, pht002566.v2.p7, pht002343.v2.p7,
pht002567.v2.p7, pht002565.v2.p7, and pht002894.v1.p7.
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